Class-action lawsuits alleging breaches in fiduciary responsibilities involving group health plans and pharmacy benefits at several blue-chip companies continue to make headlines as they command the full attention of benefit advisers.
Filed amid a federal crackdown on price transparency, the common denominator is inflated prescription drug prices. The latest involves JPMorgan, which also was sued over 401(k) forfeited funds and plan assets invested in an in-house stable value fund. It comes on the heels of two dismissed cases against Johnson & Johnson and Wells Fargo. They mirror a trend involving lawsuits over excessive 401(k) plan fees first filed nearly 20 years ago.
